Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -0.54%63 PB Ratio is 0.54 as of Jul. 14, 2026, which is 82% below its 10-year median of 2.95. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks better than 90.77% on this metric.
The historical rank and industry rank for Balaxi Pharmaceuticals's PB Ratio or its related term are showing as below:
NSE:BALAXI'
s PB Ratio Range Over the Past 10 Years
Min: 0.47 Med: 2.95 Max: 20.34
Current: 0.54
During the past 12 years, Balaxi Pharmaceuticals's highest PB Ratio was 20.34. The lowest was 0.47. And the median was 2.95.
NSE:BALAXI's PB Ratio is ranked better than 90.77% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs NSE:BALAXI: 0.54
During the past 12 months, Balaxi Pharmaceuticals's average Book Value Per Share Growth Rate was 8.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 26.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 54.00% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Balaxi Pharmaceuticals was 265.20% per year. The lowest was 8.40% per year. And the median was 53.70% per year.
Back to Basics: PB Ratio
Balaxi Pharmaceuticals (NSE:BALAXI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Balaxi Pharmaceuticals (NSE:BALAXI) has a PB Ratio of 0.54 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Balaxi Pharmaceuticals and its competitors. This is 82% below median its historical median of 2.95. Over the past decade, Balaxi Pharmaceuticals' PB Ratio has ranged from 0.47 to 20.34. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #85 out of 921 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Balaxi Pharmaceuticals' PB Ratio too high?
Balaxi Pharmaceuticals' current PB Ratio of 0.54 is 82% below median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 20.34. The Drug Manufacturers industry median PB Ratio is 1.90. Balaxi Pharmaceuticals' value of 0.54 is 71.6% below this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #85 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #85 out of 921 companies for PB Ratio. This places Balaxi Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. Balaxi Pharmaceuticals' value of 0.54 is 71.6% below this benchmark. Historically, Balaxi Pharmaceuticals' own PB Ratio has ranged from 0.47 to 20.34 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 1.90, Balaxi Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current PB Ratio of 0.54 is 71.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current PB Ratio is 0.54, which is 82% below median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current PB Ratio is 0.54, which is 82% below median its 10-year median of 2.95 and 71.6% below the Drug Manufacturers industry median of 1.90. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current PB Ratio is 0.54 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
PB Ratio: 0.54 (82% below median its 10-year median of 2.95)
GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
Industry Position: 71.6% below the Drug Manufacturers median (#85 of 921)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score
Get the complete analysis for NSE:BALAXI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
